Historique
Bulletin de Périodique
Addiction , Vol.107, n°4 - April 2012
Paru le :
26/03/2012
Année :
2012
Page(s) :
689-859
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
• In the name of treatment: ending abuses in compulsory drug detention centers [Editorial]. Jurgens R., Csete J., p. 689-691.
• Why should we need a European Federation of Addiction Societies? [Editorial]. Mann K.F., p. 692-693.
• Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials [For debate]. Donovan D.M., Bigelow G.E., Brigham G.S., Carroll K.M., Cohen A.J., Gardin J.G., et al., p. 694-708.
• Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders [For debate]. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R., p. 709-718.
• 'Nothing is more practical than a good theory': outcome measures in addictions treatment research. Del Boca F.K., Darkes J., p. 719-720.
• How to measure outcome in clinical trials of substance abuse treatment. Uchtenhagen A., p. 720-722.
• The mountain roared and brought forth a mouse*: comments on the results of an expert panel on standardization of drug dependence treatment trial outcome variables. Buhringer G., p. 722-723.
• More mice or a better mouse trap? Reflections on primary outcome indices in illicit drug dependence treatment research. Donovan D.M., p. 723-724.
• Other outcomes in treatments for substance-use disorders: a call for action. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R., p. 725-726.
• Addiction Research Centres and the Nurturing of Creativity. National Institute on Alcohol and Drugs Policies, Brazil. Laranjeira R., Mitsuhiro S.S., p. 727-732.
• Interventions to prevent substance use and risky sexual behaviour in young people: a systematic review. Jackson C., Geddes R., Haw S., Frank J., p. 733-747.
• Changes in sobriety in the Swedish population over three decades: age, period or cohort effects? Ahacic K., Kennison R.F., Kareholt I., p. 748-755.
• Age and ethnic differences in the onset, persistence and recurrence of alcohol use disorder. Grant J.D., Verges A., Jackson K.M., Trull T.J., Sher K.J., Bucholz K.K., p. 756-765.
• Scheduling of newly emerging drugs: a critical review of decisions over 40 years. Coulson C., Caulkins J.P., p. 766-773.
• Commentary on Coulson & Caulkins (2012): Optimizing drug scheduling. Kleiman M.A., p. 774-775.
• Use of other opioids during methadone therapy: a population-based study. Kurdyak P., Gomes T., Yao Z., Mamdani M.M., Hellings C., Fischer B., et al., p. 776-780.
• Commentary on Kurdyak et al. (2012): Methadone and other opioids - need for coordinated prescribing. Dobbin M.D., McDonough M.A., p. 781-782.
• Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Kirkpatrick M.G., Gunderson E.W., Johanson C.E., Levin F.R., Foltin R.W., Hart C.L., p. 783-791.
• Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Freeman T.P., Morgan C.J.A., Vaughn-Jones J., Hussain N., Karimi K., Curran H.V., p. 792-800.
• Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Gartner C.E., Barendregt J.J., Wallace A., Hall W.D., p. 801-809.
• Greater prevalence of proposed DSM-5 nicotine use disorder compared to DSM-IV nicotine dependence in treated adolescents and young adults. Chung T., Martin C.S., Maisto S.A., Cornelius J.R., Clark D.B., p. 810-818.
• Academic achievement and smoking initiation in adolescence: a general growth mixture analysis. Morin A.J., Rodriguez D., Fallu J.S., Maiano C., Janosz M., p. 819-828.
• A randomized controlled trial of stage-matched intervention for smoking cessation in cardiac out-patients. Chan S.S., Leung D.Y., Wong D.C., Lau C.P., Wong V.T., Lam T.H., p. 829-837.
• Young people's beliefs about the harmfulness of alcohol, cannabis and tobacco for mental disorders: findings from two Australian national youth surveys. Yap M.B.H., Reavley N.J., Jorm A.F., p. 838-847.
• Alcohol-dependence: the current French craze for baclofen. Rolland B., Bordet R., Cottencin O., p. 848-849.
• The call for evidence-based drink and driving policies in Brazil. Andreuccetti G., HB D.E.C., Cherpitel C.J., Leyton V., p. 849-850.
• In the name of treatment: ending abuses in compulsory drug detention centers [Editorial]. Jurgens R., Csete J., p. 689-691.
• Why should we need a European Federation of Addiction Societies? [Editorial]. Mann K.F., p. 692-693.
• Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials [For debate]. Donovan D.M., Bigelow G.E., Brigham G.S., Carroll K.M., Cohen A.J., Gardin J.G., et al., p. 694-708.
• Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders [For debate]. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R., p. 709-718.
• 'Nothing is more practical than a good theory': outcome measures in addictions treatment research. Del Boca F.K., Darkes J., p. 719-720.
• How to measure outcome in clinical trials of substance abuse treatment. Uchtenhagen A., p. 720-722.
• The mountain roared and brought forth a mouse*: comments on the results of an expert panel on standardization of drug dependence treatment trial outcome variables. Buhringer G., p. 722-723.
• More mice or a better mouse trap? Reflections on primary outcome indices in illicit drug dependence treatment research. Donovan D.M., p. 723-724.
• Other outcomes in treatments for substance-use disorders: a call for action. Tiffany S.T., Friedman L., Greenfield S.F., Hasin D.S., Jackson R., p. 725-726.
• Addiction Research Centres and the Nurturing of Creativity. National Institute on Alcohol and Drugs Policies, Brazil. Laranjeira R., Mitsuhiro S.S., p. 727-732.
• Interventions to prevent substance use and risky sexual behaviour in young people: a systematic review. Jackson C., Geddes R., Haw S., Frank J., p. 733-747.
• Changes in sobriety in the Swedish population over three decades: age, period or cohort effects? Ahacic K., Kennison R.F., Kareholt I., p. 748-755.
• Age and ethnic differences in the onset, persistence and recurrence of alcohol use disorder. Grant J.D., Verges A., Jackson K.M., Trull T.J., Sher K.J., Bucholz K.K., p. 756-765.
• Scheduling of newly emerging drugs: a critical review of decisions over 40 years. Coulson C., Caulkins J.P., p. 766-773.
• Commentary on Coulson & Caulkins (2012): Optimizing drug scheduling. Kleiman M.A., p. 774-775.
• Use of other opioids during methadone therapy: a population-based study. Kurdyak P., Gomes T., Yao Z., Mamdani M.M., Hellings C., Fischer B., et al., p. 776-780.
• Commentary on Kurdyak et al. (2012): Methadone and other opioids - need for coordinated prescribing. Dobbin M.D., McDonough M.A., p. 781-782.
• Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Kirkpatrick M.G., Gunderson E.W., Johanson C.E., Levin F.R., Foltin R.W., Hart C.L., p. 783-791.
• Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Freeman T.P., Morgan C.J.A., Vaughn-Jones J., Hussain N., Karimi K., Curran H.V., p. 792-800.
• Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Gartner C.E., Barendregt J.J., Wallace A., Hall W.D., p. 801-809.
• Greater prevalence of proposed DSM-5 nicotine use disorder compared to DSM-IV nicotine dependence in treated adolescents and young adults. Chung T., Martin C.S., Maisto S.A., Cornelius J.R., Clark D.B., p. 810-818.
• Academic achievement and smoking initiation in adolescence: a general growth mixture analysis. Morin A.J., Rodriguez D., Fallu J.S., Maiano C., Janosz M., p. 819-828.
• A randomized controlled trial of stage-matched intervention for smoking cessation in cardiac out-patients. Chan S.S., Leung D.Y., Wong D.C., Lau C.P., Wong V.T., Lam T.H., p. 829-837.
• Young people's beliefs about the harmfulness of alcohol, cannabis and tobacco for mental disorders: findings from two Australian national youth surveys. Yap M.B.H., Reavley N.J., Jorm A.F., p. 838-847.
• Alcohol-dependence: the current French craze for baclofen. Rolland B., Bordet R., Cottencin O., p. 848-849.
• The call for evidence-based drink and driving policies in Brazil. Andreuccetti G., HB D.E.C., Cherpitel C.J., Leyton V., p. 849-850.
Dépouillements
Ajouter le résultat à votre sélection
Aims Decisions on whether and how to 'schedule' drugs (i.e. to determine their legal status and penalties to be applied for sale or possession) are often heavily criticized. We sought to assess more comprehensively the results of such decisions [...]
T. P. FREEMAN ;
C. J. A. MORGAN ;
J. VAUGHN-JONES ;
N. HUSSAIN ;
K. KARIMI ;
H. V. CURRAN
|
2012
Dans Addiction (Vol.107, n°4, April 2012) Article : Périodique
Dans Addiction (Vol.107, n°4, April 2012) Article : Périodique
Aims - Use of the stimulant drug mephedrone increased dramatically in 2009, and it is still available in the United Kingdom after being controlled in April 2010. This study aimed to assess mephedrone's acute cognitive and subjective effects.
De[...]
M. B. H. YAP ;
N. J. REAVLEY ;
A. F. JORM
|
2012
Dans Addiction (Vol.107, n°4, April 2012) Article : Périodique
Dans Addiction (Vol.107, n°4, April 2012) Article : Périodique
Aims Using cross-sectional national survey data, we assessed young peoples' beliefs about the role of alcohol, tobacco and marijuana in the prevention and treatment of mental disorders as well as the predictors of these beliefs. We also compare[...]